All articles tagged with #endocrinology
New research reexamines Simonetta Vespucci, Botticelli’s famed model, and suggests a slowly growing pituitary tumor—possibly secreting growth hormone and prolactin—plus a pituitary apoplexy event could explain her sudden death in 1476, with changes in Botticelli’s portraits and contemporary illness accounts supporting the reading and offering an alternative to tuberculosis, though no direct tissue evidence remains.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex’s history and expanding its commercial endocrinology portfolio with Crinetics’ programs in obesity, diabetes and related endocrine diseases.
An endocrinologist suggests eight practical daily habits to support hormone health: manage stress, get adequate sleep with a consistent wake time, engage in some movement each day, spend time outside, eat sufficient protein and fiber, and consider light intermittent fasting if feasible—principles that align with overall health guidance.
A large ENDO 2026 study using NIH All of Us data and Fitbit shows adults with obesity starting GLP-1 receptor agonists reduced daily steps (from about 5,047 to 4,487) and moderate-to-vigorous physical activity (28 minutes to 22 minutes). Declines were most pronounced in men and those with joint or muscle pain; age averaged 52.7 years and 78.6% were women. The findings suggest weight loss from GLP-1 drugs does not automatically increase activity, underscoring that exercise and targeted interventions remain essential alongside these medications.
A Swiss study of 94 young men found cannabis users had about 23% higher testosterone than non-users, plus raised levels of androstenedione and DHT, while adrenal androgens were unchanged. The effects appear localized to the testes, with two progesterone‑related metabolites also elevated, suggesting cannabis alters a broader hormonal network rather than simply lowering testosterone. The brain’s role remains uncertain, and implications for fertility are not yet clear.
The International PCOS Network renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its metabolic and endocrine nature and improve understanding, diagnosis, and treatment; proponents hope the change will help more women receive faster referrals and appropriate care, though experts say a name change alone won't cure the condition, which still requires symptom management.
Doctors say the online cortisol scare is largely hype: cortisol is a normal, useful hormone with small, natural spikes; extreme claims and ads promising quick fixes lack solid evidence. Rare conditions like Cushing’s or Addison’s exist, but most people don’t have dangerous imbalances. Focus on stress management and consult a clinician rather than chasing supplements or TikTok guidance.
Experts rename polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its broader hormonal and metabolic features, not just ovarian cysts; diagnosis centers on irregular periods and signs of high androgens, with infertility and pregnancy risks acknowledged. Treatment emphasizes lifestyle changes and individualized options such as metformin, anti-androgens, and hormonal birth control based on fertility goals.
After a 14-year global consensus involving 56 organizations and about 22,000 participants, Polycystic Ovary Syndrome is officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its systemic hormonal and metabolic nature. The rename aims to reduce stigma, improve diagnosis, and align clinical practice over the next three years, with around 1 in 8 women affected by PMOS. The effort was led by researchers including Prof. Helena Teede and advocacy by Lorna Berry, highlighting the shift away from a cyst-centric view to a broader endocrine health perspective.
A global health consortium renames polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better capture its multisystem nature, remove the misleading focus on ovaries, and reduce stigma. After 14 years of collaboration, the group plans to push PMOS into ICD classifications within three years and raise public and professional awareness. The condition affects about 170 million people worldwide, with up to 70% undiagnosed, and often involves metabolic, endocrine, psychological, and dermatological symptoms beyond reproduction. The renaming emphasizes insulin resistance and diabetes risk, potentially guiding research, screening, and treatment, including the continued, and sometimes off-label, use of drugs like metformin. The Lancet policy paper outlines the strategy to educate globally and secure official ICD updates.
Global experts publish in The Lancet a multiyear, multistakeholder process renaming polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to avoid the cyst misnomer and better reflect its hormonal and metabolic features, with an eight‑stage plan—from dissemination and resource development to health‑system integration, policy alignment, and international guideline updates—aimed at clearer diagnosis and improved care.
Health researchers have renamed PCOS to PMOS (polyendocrine metabolic ovarian syndrome) to better reflect its wide hormonal and metabolic effects; a global consortium says the old name contributed to delayed diagnosis, stigma, and siloed research. The change could alter clinical care by prompting broader metabolic and cardiovascular screening, expand funding beyond reproductive health, and spur new treatments for the roughly 10–13% of reproductive-age women affected.
A Lancet-published renaming led by endocrinologist Helena Teede changes polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to reflect the disorder’s wide metabolic and cardiovascular effects. Diagnosis shifts away from ovarian cysts, using 2 of 3 criteria (androgens, irregular menses, or high AMH/ovarian follicles), with ultrasound needing less emphasis. The rename is intended to broaden research funding and change treatment approaches beyond fertility, with PMOS slated to replace PCOS in ICD classification by 2028, though some opposition from those tied to the PCOS branding is expected.
After more than a decade of global consultation, polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its hormonal and metabolic impacts. Led by Prof. Helena Teede and backed by 56 medical and patient groups across six continents, the change aims to reduce misunderstanding and improve diagnosis and care, with the new name to be incorporated into international guidelines by 2028.
Live Science reports that polycystic ovary syndrome (PCOS) will be renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its hormonal and metabolic nature. The term “polycystic” is considered inaccurate since arrested follicles, not cysts, drive many features, and the name has contributed to confusion and stigma. The change was led by an international coalition of 56 organizations, with input from thousands of patients and clinicians, and is set to roll out over about three years. The acronym may continue as PMOS, and there are plans to update diagnostic language beyond ovaries to mirror the systemic endocrine-metabolic effects; this may also stimulate broader research and awareness beyond gynecology.